Skip to main content

Table 1 Characteristics of collaboration networks for four classes of drugs

From: Importance of scientific collaboration in contemporary drug discovery and development: a detailed network analysis

Drug name Target class No. of papers No. of authors No. of institutions Fraction with inter-institutional collaboration Fraction with industrial participation Average clustering Assortativity Fraction of top institutions with 90% or greater collaborations
Alirocumab PCSK9 inhibitors 403 1407 908 0.72 0.429 0.015 − 0.087 0.126
Bococizumab 66 346 173 0.73 0.465 0.047 − 0.057 0.347
Evolocumab 400 1185 680 0.63 0.509 0.006 − 0.075 0.153
Sildenafil PDE5 inhibitors 8018 25,171 12,659 0.39 0.128 0.009 − 0.018 0.043
Tadalafil 2468 7918 4556 0.45 0.236 0.012 − 0.055 0.073
Vardenafil 1464 4407 2556 0.41 0.240 0.012 − 0.022 0.098
Atorvastatin Statins (HMG-CoA reductase inhibitors) 13,478 42,607 22,201 0.49 0.162 0.003 0.060 0.024
Cerivastatin 722 2725 1416 0.38 0.150 0.014 0.066 0.129
Fluvastatin 2848 9722 5112 0.36 0.131 0.020 0.021 0.079
Lovastatin 4554 15,168 7679 0.39 0.139 0.008 0.023 0.068
Pitavastatin 1228 4660 2212 0.37 0.052 0.007 0.047 0.076
Pravastatin 5356 18,214 8403 0.45 0.108 0.002 −0.016 0.047
Rosuvastatin 5285 17,718 9242 0.59 0.134 0.003 0.095 0.037
Simvastatin 12,738 43,187 21,691 0.85 0.067 0.001 0.101 0.007
Adalimumab TNF inhibitors 8756 30,178 19,734 0.61 0.126 0.003 0.026 0.020
Certolizumab pegol 1052 3639 2085 0.89 0.024 0.004 0.067 0.052
Etanercept 8521 28,705 15,002 0.55 0.187 0.006 − 0.024 0.030
Golimumab 1285 4810 2980 0.69 0.430 0.006 − 0.032 0.073
Infliximab 16,371 52,436 31,727 0.55 0.134 0.002 − 0.012 0.015
  1. Note: The significant changes of network characteristics are highlighted by bold text. The detailed descriptions for network indices are provided in the “Methods” section